Skip to main
KOD

KOD Stock Forecast & Price Target

KOD Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Kodiak Sciences Inc has made significant advancements with its Antibody Biopolymer Conjugate (ABC) platform, leading to promising investigational therapies such as tarcocimab tedromer (Zenkuda) and KSI-501. Recent data from pivotal trials indicated that KSI-101 achieved over 90% of patients reaching retinal dryness by Week 8 and demonstrated meaningful vision gains, while tarcocimab's strong performance led to increased probabilities of success (POS) for both diabetic retinopathy and wet AMD. With a solid trial execution and positive trends in patient outcomes, the outlook for Kodiak Sciences remains favorable, particularly as the company is poised to release further results from upcoming Phase 3 trials.

Bears say

Kodiak Sciences Inc. faces significant challenges stemming from previous clinical trial failures, including the Phase 3 GLEAM and GLIMMER trials for diabetic macular edema (DME) and the Phase 2b/3 DAZZLE trial for wet age-related macular degeneration (AMD), which have undermined investor confidence. The company's investigational therapies, tarcocimab tedromer and KSI-501, may struggle to achieve peak commercial revenue projections due to concerns regarding market size, penetration rates, and pricing dynamics, resulting in uncertainty around their long-term viability. Additionally, potential difficulties in securing necessary capital to support ongoing development and commercialization efforts further exacerbate the negative outlook for Kodiak Sciences's stock.

KOD has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kodiak Sciences Inc (KOD) Forecast

Analysts have given KOD a Buy based on their latest research and market trends.

According to 7 analysts, KOD has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kodiak Sciences Inc (KOD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.